Skip to content

The efficacy and safety observation study of Eravacycline treatment in patients with neutropenia and fever: A multicenter retrospective cohort study based on HIS data

The efficacy and safety observation study of Eravacycline treatment in patients with neutropenia and fever: A multicenter retrospective cohort study based on HIS data

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400089338
Enrollment
Unknown
Registered
2024-09-06
Start date
2024-09-16
Completion date
Unknown
Last updated
2024-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Granulocyte deficiency with fever

Interventions

Different subgroups of patients with neutropenia and fever:None

Sponsors

Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1) Aged 18 years or older. 2) Patients diagnosed with neutropenia accompanied by fever. The diagnosis of neutropenia accompanied by fever meets the definition in the "Chinese Clinical Application Guidelines for Antimicrobial Drugs in Patients with Neutropenia and Fever (2020 Edition)": (1) Neutropenia - refers to an absolute neutrophil count (ANC) in peripheral blood <0.5×10^9/L, or expected ANC <0.5×10^9/L within 48 hours; (2) Fever - refers to a single oral temperature =38.3°C (axillary temperature =38.0°C), or an oral temperature =38.0°C (axillary temperature =37.7°C) lasting more than 1 hour. Patients with poor general condition (especially the elderly patients) without fever or showing hypothermia can also be included. 3) The patient has received Eravacycline treatment at least 3 days or more.

Exclusion criteria

Exclusion criteria: 1) Clearly identified as neutropenia accompanied by fever caused by a single strain of Pseudomonas Aeruginosa. 2) Pregnant women and nursing mothers are advised that the investigator should choose based on the actual clinical situation.

Design outcomes

Primary

MeasureTime frame
Efficacy;

Secondary

MeasureTime frame
Safety;Characteristics of the target patients;Prescription status of Eravacycline;

Countries

China

Contacts

Public ContactSizhou Feng

Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

szfeng@ihcams.ac.cn+86 22 2360 8592

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026